Page last updated: 2024-10-16

gamma-aminobutyric acid and Premenstrual Tension

gamma-aminobutyric acid has been researched along with Premenstrual Tension in 18 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Premenstrual Tension: A term used to describe the psychological aspects of PREMENSTRUAL SYNDROME, such as the indescribable tension, depression, hostility, and increased seizure activity in women with seizure disorder.

Research Excerpts

ExcerptRelevanceReference
"Plasma gamma-aminobutyric acid (GABA) levels have been reported to be low in some patients with major depressive disorder."3.69Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. ( Bibi, KW; Halbreich, U; Kramer, GL; Petty, F; Rush, AJ; Yonkers, K, 1996)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.56)18.7374
1990's3 (16.67)18.2507
2000's5 (27.78)29.6817
2010's6 (33.33)24.3611
2020's3 (16.67)2.80

Authors

AuthorsStudies
Gao, M3
Zhang, H4
Gao, Z3
Sun, Y3
Xu, G3
Wei, F3
Wang, J3
Gao, D3
Hantsoo, L2
Payne, JL1
Sikes-Keilp, C1
Rubinow, DR1
Gao, H1
Shang, YZ1
Xia, T1
Qiao, MQ1
Zhang, HY1
Ma, YX1
Gao, X1
Sun, P1
Qiao, M1
Wei, S1
Xue, L1
De Bondt, T1
De Belder, F1
Vanhevel, F1
Jacquemyn, Y1
Parizel, PM1
Epperson, CN3
Krüger, S1
Lindstaedt, M1
Omole, F1
Hacker, Y1
Patterson, E1
Isang, M1
Bell-Carter, D1
Sundstrom-Poromaa, I1
Smith, DH1
Gong, QH2
Sabado, TN1
Li, X2
Light, A1
Wiedmann, M1
Williams, K1
Smith, SS2
Haga, K1
Mason, GF2
Sellers, E1
Gueorguieva, R1
Zhang, W1
Weiss, E1
Rothman, DL2
Krystal, JH2
Ross, LE1
Steiner, M1
Amin, Z1
Cavus, I1
Labrum, AH1
Halbreich, U1
Petty, F1
Yonkers, K1
Kramer, GL1
Rush, AJ1
Bibi, KW1
Yonkers, KA1
Hsu, FC1
Markowitz, RS1
ffrench-Mullen, JM1
Breckwoldt, M1
Keck, Ch1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder[NCT02777372]Phase 484 participants (Actual)Interventional2016-04-01Completed
Sex, GABA and Nicotine: A 1H-MRS Study[NCT01227343]54 participants (Actual)Observational2010-03-31Completed
Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen[NCT00626340]Phase 418 participants (Actual)Interventional1999-07-31Completed
Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial[NCT02427334]Phase 3210 participants (Anticipated)Interventional2015-04-30Recruiting
The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial[NCT02488538]Phase 3300 participants (Anticipated)Interventional2015-07-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Acoustic Startle Response (ASR) Magnitude Based on Menstrual Cycle Phase

Acoustic startle response (ASR) is measured during the follicular and luteal phase of the menstrual cycle in controls and those with PMDD. Magnitude of ASR is measured using the eyeblink reflex, by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. For the primary outcome of baseline ASR magnitude over the menstrual cycle, peak amplitude of the blink reflex was determined in the 20-120-ms time frame following stimulus onset relative to baseline (baseline is the average baseline electromyography (EMG) level for the 50 ms immediately preceding auditory stimulus onset). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 1 (Follicular), Month 2 (Luteal)

,
Interventiont score (Mean)
Month 1 (Follicular)Month 2 (Luteal)
Control54.256.4
Sertraline53.753.3

Impact of Sertraline on ASR Magnitude

This outcome examines the impact of luteal phase treatment with a selective serotonin reuptake inhibitor (SSRI) (PMDD group only) on acoustic startle response (ASR). ASR is measured using the eyeblink reflex, measured by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. Peak amplitude of the blink reflex is determined in the 20-120-ms time frame following stimulus onset. PMDD participants complete test day 3 (Luteal Month 3) while on sertraline and their ASR magnitude will be compared to their previous luteal test day (Luteal Month 2). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 2 (Luteal), Month 3 (Luteal)

,
Interventiont score (Mean)
Month 2 (Luteal)Month 3 (Luteal)
Control56.451.8
Sertraline53.352.2

Interleukin 6 (IL-6) Level

Blood samples were collected to measure serum interleukin-6 (IL-6). IL-6 levels were compared in the follicular and luteal phases, between Control and PMDD groups. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )

,
Interventionpicogram/milliliter (pg/mL) (Mean)
Month 1 (Follicular)Month 2 (Luteal)
Control0.4.59
Sertraline.34.4

Tumor Necrosis Factor Alpha (TNF-alpha) Level

Blood samples were collected to measure serum TNF-alpha levels in the Follicular and Luteal 1 phases. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )

,
Interventionpg/mL (Mean)
Month 1 (Follicular )Month 2 (Luteal )
Control1.271.27
Sertraline1.631.54

Comparison of Cortical GABA Levels in 4 Groups of Subjects Using Estrogen Alone, Fluoxetine Alone, Estrogen and Fluoxetine Combined in Pre and Post 4.0T Magnetic Resonance Spectroscopy Sessions.

"This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable to contact for additional information.~We only know that 18 participants completed, but as far as we know data was never analyzed for these 18 participants." (NCT00626340)
Timeframe: Healthy controls will undergo scans pre and post 3 weeks of estrogen treatment. Women with depression will undergo scans pre and post 6 weeks of treatment with estrogen alone, estrogen and fluoxetine, or fluoxetine alone

Intervention ()
All Participants0

Reviews

6 reviews available for gamma-aminobutyric acid and Premenstrual Tension

ArticleYear
Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA.
    Neuroscience and biobehavioral reviews, 2023, Volume: 149

    Topics: Biology; Female; gamma-Aminobutyric Acid; Humans; Menstrual Cycle; Premenstrual Dysphoric Disorder;

2023
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder.
    CNS drugs, 2023, Volume: 37, Issue:8

    Topics: Female; GABA Modulators; gamma-Aminobutyric Acid; Humans; Luteal Phase; Menstrual Cycle; Pregnanolon

2023
Premenstrual Dysphoric Disorder: Epidemiology and Treatment.
    Current psychiatry reports, 2015, Volume: 17, Issue:11

    Topics: Diagnosis, Differential; Diagnostic and Statistical Manual of Mental Disorders; Disease Management;

2015
A biopsychosocial approach to premenstrual dysphoric disorder.
    The Psychiatric clinics of North America, 2003, Volume: 26, Issue:3

    Topics: Adult; Child; Child Abuse, Sexual; Depression; Diagnosis, Differential; Diagnostic and Statistical M

2003
The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women.
    Pharmacology, biochemistry, and behavior, 2006, Volume: 84, Issue:4

    Topics: Affect; Depression, Postpartum; Female; gamma-Aminobutyric Acid; Humans; Menstruation; Mental Disord

2006
The association between premenstrual dysphoric disorder and other mood disorders.
    The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 15

    Topics: Biomarkers; Comorbidity; Depressive Disorder; Diagnosis, Differential; Endorphins; Family; Female; g

1997

Other Studies

12 other studies available for gamma-aminobutyric acid and Premenstrual Tension

ArticleYear
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
    Aging, 2022, 11-27, Volume: 14, Issue:22

    Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso

2022
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
    Aging, 2022, 11-27, Volume: 14, Issue:22

    Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso

2022
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
    Aging, 2022, 11-27, Volume: 14, Issue:22

    Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso

2022
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
    Aging, 2022, 11-27, Volume: 14, Issue:22

    Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso

2022
The correlation between neurosteroids and neurotransmitters with liver yang rising and liver qi stagnation types of premenstrual syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014, Volume: 30, Issue:12

    Topics: Adult; Dehydroepiandrosterone; Dopamine; Female; gamma-Aminobutyric Acid; Humans; Liver; Medicine, C

2014
Shu‑Yu capsule, a Traditional Chinese Medicine formulation, attenuates premenstrual syndrome depression induced by chronic stress constraint.
    Molecular medicine reports, 2014, Volume: 10, Issue:6

    Topics: Animals; Body Mass Index; Depression; Drugs, Chinese Herbal; Female; Fluoxetine; gamma-Aminobutyric

2014
Prefrontal GABA concentration changes in women-Influence of menstrual cycle phase, hormonal contraceptive use, and correlation with premenstrual symptoms.
    Brain research, 2015, Feb-09, Volume: 1597

    Topics: Contraceptives, Oral, Hormonal; Creatine; Estradiol; Female; Follicle Stimulating Hormone; gamma-Ami

2015
Pregabalin and edema in young women suffering from premenstrual syndrome.
    Pharmacopsychiatry, 2010, Volume: 43, Issue:5

    Topics: Adult; Analgesics; Anxiety Disorders; Edema; Female; gamma-Aminobutyric Acid; Humans; Pregabalin; Pr

2010
Easing the burden of premenstrual dysphoric disorder.
    The Journal of family practice, 2013, Volume: 62, Issue:1

    Topics: Contraceptives, Oral, Hormonal; Diagnostic and Statistical Manual of Mental Disorders; Diet; Dietary

2013
Hormonally regulated alpha(4)beta(2)delta GABA(A) receptors are a target for alcohol.
    Nature neuroscience, 2002, Volume: 5, Issue:8

    Topics: Animals; Chlorides; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Female; gamma

2002
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study.
    Archives of general psychiatry, 2002, Volume: 59, Issue:9

    Topics: Adult; Cerebral Cortex; Estradiol; Female; Follicular Phase; gamma-Aminobutyric Acid; Humans; Luteal

2002
Hypothalamic, pineal and pituitary factors in the premenstrual syndrome.
    The Journal of reproductive medicine, 1983, Volume: 28, Issue:7

    Topics: Female; gamma-Aminobutyric Acid; Humans; Premenstrual Syndrome; Serotonin

1983
Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder.
    The American journal of psychiatry, 1996, Volume: 153, Issue:5

    Topics: Adult; Depressive Disorder; Female; Follicular Phase; gamma-Aminobutyric Acid; Humans; Luteal Phase;

1996
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
    Nature, 1998, Apr-30, Volume: 392, Issue:6679

    Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid;

1998
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
    Nature, 1998, Apr-30, Volume: 392, Issue:6679

    Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid;

1998
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
    Nature, 1998, Apr-30, Volume: 392, Issue:6679

    Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid;

1998
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
    Nature, 1998, Apr-30, Volume: 392, Issue:6679

    Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid;

1998
[Premenstrual syndrome].
    Therapeutische Umschau. Revue therapeutique, 2002, Volume: 59, Issue:4

    Topics: Affect; Brain; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Premenstrual Syndr

2002